Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CAR-T Meeting 2024 | Current research and next steps to improve the understanding and management of ICAHT

Kai Rejeski • 17 Feb 2024
CAR-T Meeting 2024
General CAR-T

In this video, Kai Rejeski, MD, Memorial Sloan Kettering Cancer Center, New York, NY, briefly outlines the current research into immune effector cell-associated hematotoxicity (ICAHT). This includes the development of a fully automated system, using the R programming language, to grade this complication. This interview took place at the EBMT-EHA 6th European CAR T-cell Meeting in Valencia, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Consultancy: BMS/CELGENE
Honoraria: BMS/CELGENE, Novartis
Travel Support: Kite/Gilead, Pierre-Fabre
Research Funding: Kite/Gilead

More from Kai Rejeski

1:16
EHA/EBMT Consensus Grading of ICAHT
Kai Rejeski • 17 Feb 2024
1:14
Components of the CAR-HEMATOTOX model which allow for prediction of ICAHT following CAR-T
Kai Rejeski • 17 Feb 2024
1:32
Factors contributing to the pathogenesis of ICAHT
Kai Rejeski • 17 Feb 2024
0:41
Neutrophil recovery phenotypes observed in patients following CD19 CAR T-cell therapy
Kai Rejeski • 17 Feb 2024

Related Videos

4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
2:25
The EBMT Trainee Committee: in-person trainee day at EBMT 2024 and upcoming initiatives
Claire Horgan • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals